C07K 16/36
Against blood coagulation factors
Official title: against blood coagulation factors
C07K16/36 (Against blood coagulation factors) appears on 501 US grants and 803 published applications in this corpus.
Search patents in C07K- Granted patents
- 501
- Published applications
- 803
- Assignees
- 332
- Inventors
- 1,348
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 5 | 0 |
| 1988 | 1 | 0 |
| 1989 | 3 | 0 |
| 1990 | 0 | 0 |
| 1991 | 6 | 0 |
| 1992 | 12 | 0 |
| 1993 | 11 | 0 |
| 1994 | 8 | 0 |
| 1995 | 5 | 0 |
| 1996 | 2 | 0 |
| 1997 | 12 | 0 |
| 1998 | 12 | 0 |
| 1999 | 13 | 0 |
| 2000 | 6 | 0 |
| 2001 | 9 | 2 |
| 2002 | 8 | 13 |
| 2003 | 7 | 27 |
| 2004 | 7 | 18 |
| 2005 | 5 | 24 |
| 2006 | 7 | 25 |
| 2007 | 11 | 23 |
| 2008 | 5 | 16 |
| 2009 | 11 | 35 |
| 2010 | 14 | 19 |
| 2011 | 11 | 25 |
| 2012 | 14 | 20 |
| 2013 | 14 | 22 |
| 2014 | 14 | 26 |
| 2015 | 17 | 28 |
| 2016 | 18 | 29 |
| 2017 | 18 | 32 |
| 2018 | 29 | 40 |
| 2019 | 16 | 46 |
| 2020 | 20 | 51 |
| 2021 | 25 | 54 |
| 2022 | 31 | 46 |
| 2023 | 13 | 53 |
| 2024 | 28 | 49 |
| 2025 | 37 | 44 |
| 2026 | 16 | 36 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti D-Dimer recombinant antibodies, methods and uses thereof15 Sep 2026US 12,735,504 B2F. Hoffmann-La Roche AG
- Protein biomarker indicators of neurological injury and/or disease and methods of use thereof15 Sep 2026US 12,736,547 B2Brainbox Solutions, Inc.
- Monoclonal antibody against human activated protein C and preparation and use thereof18 Aug 2026US 12,708,662 B2Oklahoma Medical Research Foundation
- Protein heterodimer and use thereof18 Aug 2026US 12,709,638 B2Ningbo Innovative Mechanism Bioscience LLC
- Stable formulations of immunoglobulin single variable domains23 Jun 2026US 12,662,550 B2Ablynx N. V.
- Factor xi a2 domain-binding antibodies and methods of use thereof8 Oct 2026US 2026/0308276 A1Regeneron Pharmaceuticals, Inc.
- Methods and means for the production of ig-like molecules8 Oct 2026US 2026/0308655 A1Merus N.V.
- Combined use of bispecific antibody binding to activated coagulation factor ix and coagulation factor x with blood coagulation factor x for treating subject with hemophilia a1 Oct 2026US 2026/0295022 A1KM Biologics Co., Ltd.
- Method for the reduction of host cell proteins in affinity chromatography10 Sep 2026US 2026/0265295 A1Genentech, Inc.
- Protein biomarker indicators of neurological injury and/or disease and methods of use thereof10 Sep 2026US 2026/0266850 A1Brainbox Solutions, Inc.
Most cited
By later US patents
- Bispecific antibodies145US 9,334,331 B2Chugai Seiyaku Kabushiki Kaisha · 2016
- Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them110US 5,171,844 AGist-Brocades N.W. · 1992
- Pancreatic cancer targets and uses thereof104US 7,473,531 B1Colora Corporation · 2009
- Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody88US 6,677,436 B1Chugai Seiyaku Kabushiki Kaisha · 2004
- Bispecific antibody substituting for functional proteins78US 8,062,635 B2Chugai Seiyaku Kabushiki Kaisha · 2011